Psychopharmacology

, Volume 231, Issue 22, pp 4323–4335 | Cite as

Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity

  • Elizabeth Murray
  • Sietske Brouwer
  • Rob McCutcheon
  • Catherine J. Harmer
  • Philip J. Cowen
  • Ciara McCabe
Original Investigation

Abstract

Rationale

Opioid antagonism reduces the consumption of palatable foods in humans but the neural substrates implicated in these effects are less well understood.

Objectives

The aim of the present study was to examine the effects of the opioid antagonist, naltrexone, on neural response to rewarding and aversive sight and taste stimuli.

Methods

We used functional magnetic resonance imaging (fMRI) to examine the neural responses to the sight and taste of pleasant (chocolate) and aversive (mouldy strawberry) stimuli in 20 healthy volunteers who received a single oral dose of naltrexone (50 mg) and placebo in a double-blind, repeated-measures cross-over, design.

Results

Relative to placebo, naltrexone decreased reward activation to chocolate in the dorsal anterior cingulate cortex and caudate, and increased aversive-related activation to unpleasant strawberry in the amygdala and anterior insula.

Conclusions

These findings suggest that modulation of key brain areas involved in reward processing, cognitive control and habit formation such as the dorsal anterior cingulate cortex (dACC) and caudate might underlie reduction in food intake with opioid antagonism. Furthermore we show for the first time that naltrexone can increase activations related to aversive food stimuli. These results support further investigation of opioid treatments in obesity.

Keywords

Reward Aversion fMRI Naltrexone Food Obesity Neuroimaging Opioid antagonism 

Notes

Conflicts of interest

Dr. McCabe has acted as a consultant to P1Vital, Givaudan, GWpharma, the British Broadcasting Company (BBC) and Channel 4. Professor Harmer is a company director of Oxford Psychologists and has acted as a consultant to Servier, GlaxoSmithKline, Astra Zeneca, Johnson & Johnson, Roche, Lundbeck and P1Vital. Professor Cowen is a member of an advisory board for Lundbeck. Elizabeth Murray, Sietske Brouwer and Rob McCutcheon report no biomedical financial interests or potential conflicts of interest.

Supplementary material

213_2014_3573_MOESM1_ESM.doc (958 kb)
ESM 1(DOC 957 kb)

References

  1. Alger SA, Schwalberg MD, Bigaouette JM, Michalek AV, Howard LJ (1991) Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. Am J Clin Nutr 53:865–871PubMedGoogle Scholar
  2. Anders S, Lotze M, Erb M, Grodd W, Birbaumer N (2004) Brain activity underlying emotional valence and arousal: a response-related fMRI study. Hum Brain Mapp 23:200–209PubMedGoogle Scholar
  3. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571PubMedGoogle Scholar
  4. Belin D, Everitt BJ (2008) Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. Neuron 57:432–441PubMedGoogle Scholar
  5. Bencherif B, Guarda AS, Colantuoni C, Ravert HT, Dannals RF, Frost JJ (2005) Regional mu-opioid receptor binding in insular cortex is decreased in bulimia nervosa and correlates inversely with fasting behavior. J Nucl Med 46:1349–1351PubMedGoogle Scholar
  6. Billes SK, Greenway FL (2011) Combination therapy with naltrexone and bupropion for obesity. Expert Opin Pharmacother 12:1813–1826PubMedGoogle Scholar
  7. Borras MC, Becerra L, Ploghaus A, Gostic JM, DaSilva A, Gonzalez RG, Borsook D (2004) fMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers. J Neurophysiol 91:2723–2733PubMedGoogle Scholar
  8. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, Goodman JM, Kantor HL, Gastfriend DR, Riorden JP, Mathew RT, Rosen BR, Hyman SE (1997) Acute effects of cocaine on human brain activity and emotion. Neuron 19:591–611PubMedGoogle Scholar
  9. Cambridge VC, Ziauddeen H, Nathan PJ, Subramaniam N, Dodds C, Chamberlain SR, Koch A, Maltby K, Skeggs AL, Napolitano A, Farooqi IS, Bullmore ET, Fletcher PC (2013) Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people. Biol Psychiatry 73:887–894PubMedPubMedCentralGoogle Scholar
  10. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706–1713PubMedGoogle Scholar
  11. Colasanti A, Rabiner EA, Lingford-Hughes A, Nutt DJ (2011) Opioids and anxiety. J Psychopharmacol 25:1415–1433PubMedGoogle Scholar
  12. Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D, Erritzoe D, Tziortzi AC, Reed LJ, Lingford-Hughes AR, Waldman AD, Schruers KR, Matthews PM, Gunn RN, Nutt DJ, Rabiner EA (2012) Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. Biol Psychiatry 72(5):371–377Google Scholar
  13. Collins DL, Neelin P, Peters TM, Evans AC (1994) Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr 18:192–205PubMedGoogle Scholar
  14. de Araujo IE, Kringelbach ML, Rolls ET, Hobden P (2003a) Representation of umami taste in the human brain. J Neurophysiol 90:313–319PubMedGoogle Scholar
  15. de Araujo IE, Kringelbach ML, Rolls ET, McGlone F (2003b) Human cortical responses to water in the mouth, and the effects of thirst. J Neurophysiol 90:1865–1876PubMedGoogle Scholar
  16. Dean AJ, Saunders JB, Jones RT, Young RM, Connor JP, Lawford BR (2006) Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. J Psychiatry Neurosci 31:38–45PubMedPubMedCentralGoogle Scholar
  17. Drewnowski A, Krahn DD, Demitrack MA, Nairn K, Gosnell BA (1992) Taste responses and preferences for sweet high-fat foods: evidence for opioid involvement. Physiol Behav 51:371–379PubMedGoogle Scholar
  18. Drewnowski A, Krahn DD, Demitrack MA, Nairn K, Gosnell BA (1995) Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters. Am J Clin Nutr 61:1206–1212PubMedGoogle Scholar
  19. Fantino M, Hosotte J, Apfelbaum M (1986) An opioid antagonist, naltrexone, reduces preference for sucrose in humans. Am J Physiol 251:R91–R96PubMedGoogle Scholar
  20. Faurion A, Cerf B, Le Bihan D, Pillias AM (1998) fMRI study of taste cortical areas in humans. Ann N Y Acad Sci 855:535–545PubMedGoogle Scholar
  21. Fawcett J, Clark DC, Scheftner WA, Gibbons RD (1983) Assessing anhedonia in psychiatric patients. Arch Gen Psychiatry 40:79–84PubMedGoogle Scholar
  22. Filbey FM, Myers US, Dewitt S (2012) Reward circuit function in high BMI individuals with compulsive overeating: similarities with addiction. Neuroimage 63:1800–1806PubMedGoogle Scholar
  23. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for DSM-IV axis I disorders: clinical version. American Psychiatric Press, WashingtonGoogle Scholar
  24. Fitzgerald DA, Posse S, Moore GJ, Tancer ME, Nathan PJ, Phan KL (2004) Neural correlates of internally-generated disgust via autobiographical recall: a functional magnetic resonance imaging investigation. Neurosci Lett 370:91–96PubMedGoogle Scholar
  25. Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC (1994) Assessing the significance of focal activations using their spatial extent. Hum Brain Mapp 1:214–220Google Scholar
  26. Friston KJ, Glaser DE, Henson RN, Kiebel S, Phillips C, Ashburner J (2002) Classical and Bayesian inference in neuroimaging: applications. Neuroimage 16:484–512PubMedGoogle Scholar
  27. Garavan H, Pankiewicz J, Bloom A, Cho JK, Sperry L, Ross TJ, Salmeron BJ, Risinger R, Kelley D, Stein EA (2000) Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am J Psychiatry 157:1789–1798PubMedGoogle Scholar
  28. Garcia-Garcia I, Narberhaus A, Marques-Iturria I, Garolera M, Radoi A, Segura B, Pueyo R, Ariza M, Jurado MA (2013) Neural responses to visual food cues: insights from functional magnetic resonance imaging. Eur Eat Disord Rev 21:89–98PubMedGoogle Scholar
  29. Garner DM, Olmsted MP, Bohr Y, Garfinkel PE (1982) The eating attitudes test: psychometric features and clinical correlates. Psychol Med 12:871–878PubMedGoogle Scholar
  30. Ghitza UE, Preston KL, Epstein DH, Kuwabara H, Endres CJ, Bencherif B, Boyd SJ, Copersino ML, Frost JJ, Gorelick DA (2010) Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatients. Biol Psychiatry 68:697–703PubMedPubMedCentralGoogle Scholar
  31. Goldstein RZ, Volkow ND (2002) Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159:1642–1652PubMedPubMedCentralGoogle Scholar
  32. Good AJ, Westbrook RF (1995) Effects of a microinjection of morphine into the amygdala on the acquisition and expression of conditioned fear and hypoalgesia in rats. Behav Neurosci 109:631–641PubMedGoogle Scholar
  33. Gorelick DA, Kim YK, Bencherif B, Boyd SJ, Nelson R, Copersino M, Endres CJ, Dannals RF, Frost JJ (2005) Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry 57:1573–1582PubMedGoogle Scholar
  34. Gracely RH, Dubner R, Wolskee PJ, Deeter WR (1983) Placebo and naloxone can alter post-surgical pain by separate mechanisms. Nature 306:264–265PubMedGoogle Scholar
  35. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E (2010) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376:595–605PubMedGoogle Scholar
  36. Harmer CJ, Cowen PJ (2013) ‘It's the way that you look at it’—a cognitive neuropsychological account of SSRI action in depression. Philos Trans R Soc Lond B Biol Sci 368:20120407PubMedPubMedCentralGoogle Scholar
  37. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563–583PubMedGoogle Scholar
  38. Hetherington MM, Vervaet N, Blass E, Rolls BJ (1991) Failure of naltrexone to affect the pleasantness or intake of food. Pharmacol Biochem Behav 40:185–190PubMedGoogle Scholar
  39. Hillemacher T, Heberlein A, Muschler MA, Bleich S, Frieling H (2011) Opioid modulators for alcohol dependence. Expert Opin Investig Drugs 20:1073–1086PubMedGoogle Scholar
  40. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K (2013) Effects of naltrexone sustained-release/bupropion sustained release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 36(12):4022–4029Google Scholar
  41. Horder J, Harmer CJ, Cowen PJ, McCabe C (2010) Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. Int J Neuropsychopharmacol: 1–11Google Scholar
  42. Horder J, Browning M, Di Simplicio M, Cowen PJ, Harmer CJ (2012) Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. J Psychopharmacol 26:125–132PubMedGoogle Scholar
  43. http://www.who.int/mediacentre/factsheets/fs311/en/ (2012) World Health organisation
  44. Katsiki N, Hatzitolios AI, Mikhailidis DP (2011) Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: ‘a new kid on the block’? Ann Med 43:249–258PubMedGoogle Scholar
  45. Keedwell PA, Andrew C, Williams SC, Brammer MJ, Phillips ML (2005) The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry 58:843–853PubMedGoogle Scholar
  46. Kelley AE, Berridge KC (2002) The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 22:3306–3311PubMedGoogle Scholar
  47. Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, Zhang M (2002) Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav 76:365–377PubMedGoogle Scholar
  48. Knutson B, Adams CM, Fong GW, Hommer D (2001) Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci 21:RC159PubMedGoogle Scholar
  49. Koppert W, Angst M, Alsheimer M, Sittl R, Albrecht S, Schuttler J, Schmelz M (2003) Naloxone provokes similar pain facilitation as observed after short-term infusion of remifentanil in humans. Pain 106:91–99PubMedGoogle Scholar
  50. Koppert W, Filitz J, Troster A, Ihmsen H, Angst M, Flor H, Schuttler J, Schmelz M (2005) Activation of naloxone-sensitive and -insensitive inhibitory systems in a human pain model. J Pain 6:757–764PubMedGoogle Scholar
  51. Kosten T, Silverman DG, Fleming J, Kosten TA, Gawin FH, Compton M, Jatlow P, Byck R (1992) Intravenous cocaine challenges during naltrexone maintenance: a preliminary study. Biol Psychiatry 32:543–548PubMedGoogle Scholar
  52. Lee MW, Fujioka K (2009) Naltrexone for the treatment of obesity: review and update. Expert Opin Pharmacother 10:1841–1845PubMedGoogle Scholar
  53. Liang NC, Bello NT, Moran TH (2013) Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations. Int J Obes (Lond) 37:272–278Google Scholar
  54. Liberzon I, Zubieta JK, Fig LM, Phan KL, Koeppe RA, Taylor SF (2002) mu-Opioid receptors and limbic responses to aversive emotional stimuli. Proc Natl Acad Sci U S A 99:7084–7089PubMedPubMedCentralGoogle Scholar
  55. Lieberman MD, Cunningham WA (2009) Type I and Type II error concerns in fMRI research: re-balancing the scale. Soc Cogn Affect Neurosci 4:423–428PubMedPubMedCentralGoogle Scholar
  56. Littleton J, Zieglgansberger W (2003) Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 12(Suppl 1):S3–S11PubMedGoogle Scholar
  57. Liu X, Hairston J, Schrier M, Fan J (2011) Common and distinct networks underlying reward valence and processing stages: a meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev 35:1219–1236PubMedPubMedCentralGoogle Scholar
  58. Makowski CT, Gwinn KM, Hurren KM (2011) Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obes Facts 4:489–494PubMedGoogle Scholar
  59. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1987) Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci 7:2445–2464PubMedGoogle Scholar
  60. Marrazzi MA, Kinzie J, Luby ED (1995) A detailed longitudinal analysis on the use of naltrexone in the treatment of bulimia. Int Clin Psychopharmacol 10:173–176PubMedGoogle Scholar
  61. Mason BJ, Goodman AM, Dixon RM, Hameed MH, Hulot T, Wesnes K, Hunter JA, Boyeson MG (2002) A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 27:596–606PubMedGoogle Scholar
  62. McCabe C, Cowen PJ, Harmer CJ (2009) Neural representation of reward in recovered depressed patients. Psychopharmacology (Berl) 205:667–677Google Scholar
  63. McCabe C, Mishor Z, Cowen PJ, Harmer CJ (2010) Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry 67:439–445PubMedPubMedCentralGoogle Scholar
  64. McCabe C, Huber A, Harmer CJ, Cowen PJ (2011) The D2 antagonist sulpiride modulates the neural processing of both rewarding and aversive stimuli in healthy volunteers. Psychopharmacology (Berl) 217:271–278Google Scholar
  65. McCabe C, Woffindale C, Harmer CJ, Cowen PJ (2012) Neural processing of reward and punishment in young people at increased familial risk of depression. Biol Psychiatry 1;72(7):588–594Google Scholar
  66. McElroy SL, Guerdjikova AI, Kim DD, Burns C, Harris-Collazo R, Landbloom R, Dunayevich E (2013) Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study. Prim Care Companion CNS Disord 15Google Scholar
  67. Migliori GB, Raviglione MC, Schaberg T, Davies PD, Zellweger JP, Grzemska M, Mihaescu T, Clancy L, Casali L (1999) Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J 14:978–992PubMedGoogle Scholar
  68. Miotto K, McCann M, Basch J, Rawson R, Ling W (2002) Naltrexone and dysphoria: fact or myth? Am J Addict 11:151–160PubMedGoogle Scholar
  69. Morrison SE, Salzman CD (2010) Re-valuing the amygdala. Curr Opin Neurobiol 20:221–230PubMedPubMedCentralGoogle Scholar
  70. Nathan PJ, Bullmore ET (2009) From taste hedonics to motivational drive: central mu-opioid receptors and binge-eating behaviour. Int J Neuropsychopharmacol 12:995–1008PubMedGoogle Scholar
  71. Nathan PJ, O'Neill BV, Napolitano A, Bullmore ET (2011) Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther 17:490–505PubMedGoogle Scholar
  72. Nathan PJ, Bush MA, Tao WX, Koch A, Davies KM, Maltby K, O'Neill BV, Napolitano A, Skeggs AL, Brooke AC, Richards DB, Williams PM, Bullmore ET (2012) Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the mu-opioid receptor inverse agonist GSK1521498. J Clin Pharmacol 52:1456–1467PubMedGoogle Scholar
  73. Nielsen CK, Simms JA, Li R, Mill D, Yi H, Feduccia AA, Santos N, Bartlett SE (2012) delta-Opioid receptor function in the dorsal striatum plays a role in high levels of ethanol consumption in rats. J Neurosci 32:4540–4552PubMedGoogle Scholar
  74. Nitschke JB, Sarinopoulos I, Mackiewicz KL, Schaefer HS, Davidson RJ (2006) Functional neuroanatomy of aversion and its anticipation. Neuroimage 29:106–116PubMedGoogle Scholar
  75. Nogueiras R, Romero-Pico A, Vazquez MJ, Novelle MG, Lopez M, Dieguez C (2012) The opioid system and food intake: homeostatic and hedonic mechanisms. Obes Facts 5:196–207PubMedGoogle Scholar
  76. O'Doherty J, Rolls ET, Francis S, Bowtell R, McGlone F (2001) Representation of pleasant and aversive taste in the human brain. J Neurophysiol 85:1315–1321PubMedGoogle Scholar
  77. Oldfield RC (1971) The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9:97–113PubMedGoogle Scholar
  78. Paton JJ, Belova MA, Morrison SE, Salzman CD (2006) The primate amygdala represents the positive and negative value of visual stimuli during learning. Nature 439:865–870PubMedPubMedCentralGoogle Scholar
  79. Pavlovic ZW, Cooper ML, Bodnar RJ (1996) Opioid antagonists in the periaqueductal gray inhibit morphine and beta-endorphin analgesia elicited from the amygdala of rats. Brain Res 741:13–26PubMedGoogle Scholar
  80. Petrovic P, Pleger B, Seymour B, Kloppel S, De Martino B, Critchley H, Dolan RJ (2008) Blocking central opiate function modulates hedonic impact and anterior cingulate response to rewards and losses. J Neurosci 28:10509–10516PubMedPubMedCentralGoogle Scholar
  81. Porrino LJ, Lyons D, Smith HR, Daunais JB, Nader MA (2004) Cocaine self-administration produces a progressive involvement of limbic, association, and sensorimotor striatal domains. J Neurosci 24:3554–3562PubMedGoogle Scholar
  82. Rabiner EA, Beaver J, Makwana A, Searle G, Long C, Nathan PJ, Newbould RD, Howard J, Miller SR, Bush MA, Hill S, Reiley R, Passchier J, Gunn RN, Matthews PM, Bullmore ET (2011) Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol Psychiatry 16(826–35):785Google Scholar
  83. Rolls ET, McCabe C (2007) Enhanced affective brain representations of chocolate in cravers vs. non-cravers. Eur J Neurosci 26:1067–1076PubMedGoogle Scholar
  84. Rolls BJ, Rolls ET, Rowe EA, Sweeney K (1981) Sensory specific satiety in man. Physiol Behav 27:137–142PubMedGoogle Scholar
  85. Rolls ET, Kringelbach ML, de Araujo IE (2003) Different representations of pleasant and unpleasant odours in the human brain. Eur J Neurosci 18:695–703PubMedGoogle Scholar
  86. Sander D, Grafman J, Zalla T (2003) The human amygdala: an evolved system for relevance detection. Rev Neurosci 14:303–316PubMedGoogle Scholar
  87. Schienle A, Schafer A, Hermann A, Vaitl D (2009) Binge-eating disorder: reward sensitivity and brain activation to images of food. Biol Psychiatry 65:654–661PubMedGoogle Scholar
  88. Scinska A, Koros E, Polanowska E, Kukwa A, Bogucka-Bonikowska A, Kostowski W, Habrat B, Bienkowski P (2000) An opioid receptor antagonist, naltrexone, does not alter taste and smell responses in humans. Pol J Pharmacol 52:397–402PubMedGoogle Scholar
  89. Sheth SA, Mian MK, Patel SR, Asaad WF, Williams ZM, Dougherty DD, Bush G, Eskandar EN (2012) Human dorsal anterior cingulate cortex neurons mediate ongoing behavioural adaptation. Nature 488:218–221PubMedPubMedCentralGoogle Scholar
  90. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P (1995) A scale for the assessment of hedonic tone the Snaith–Hamilton Pleasure Scale. Br J Psychiatry 167:99–103PubMedGoogle Scholar
  91. Spetter MS, de Graaf C, Viergever MA, Smeets PA (2012) Anterior cingulate taste activation predicts ad libitum intake of sweet and savory drinks in healthy, normal-weight men. J Nutr 142:795–802PubMedGoogle Scholar
  92. Stice E, Spoor S, Bohon C, Small DM (2008) Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science 322:449–452PubMedGoogle Scholar
  93. Stice E, Yokum S, Bohon C, Marti N, Smolen A (2010) Reward circuitry responsivity to food predicts future increases in body mass: moderating effects of DRD2 and DRD4. Neuroimage 50:1618–1625PubMedPubMedCentralGoogle Scholar
  94. Stice E, Yokum S, Burger KS, Epstein LH, Small DM (2011) Youth at risk for obesity show greater activation of striatal and somatosensory regions to food. J Neurosci 31:4360–4366PubMedPubMedCentralGoogle Scholar
  95. Streeton C, Whelan G (2001) Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 36:544–552PubMedGoogle Scholar
  96. Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Angrist B, Gatley SJ, Logan J, Ding YS, Pappas N (1999) Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry 156:19–26PubMedGoogle Scholar
  97. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, Jayne M, Ma Y, Wong C (2006) Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 26:6583–6588PubMedGoogle Scholar
  98. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F (2011) Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A 108:15037–15042PubMedPubMedCentralGoogle Scholar
  99. von Zerssen D, Strian F, Schwarz D (1974) Evaluation of depressive states, especially in longitudinal studies. Mod Probl Pharmacopsychiatry 7:189–202Google Scholar
  100. Wacker J, Dillon DG, Pizzagalli DA (2009) The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia: integration of resting EEG, fMRI, and volumetric techniques. Neuroimage 46:327–337PubMedPubMedCentralGoogle Scholar
  101. Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, Kosslyn SM, Rose RM, Cohen JD (2004) Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 303:1162–1167PubMedGoogle Scholar
  102. Wicker B, Keysers C, Plailly J, Royet JP, Gallese V, Rizzolatti G (2003) Both of us disgusted in My insula: the common neural basis of seeing and feeling disgust. Neuron 40:655–664PubMedGoogle Scholar
  103. Wilson JL, Jenkinson M, de Araujo I, Kringelbach ML, Rolls ET, Jezzard P (2002) Fast, fully automated global and local magnetic field optimization for fMRI of the human brain. Neuroimage 17:967–976PubMedGoogle Scholar
  104. Woolley JD, Lee BS, Taha SA, Fields HL (2007) Nucleus accumbens opioid signaling conditions short-term flavor preferences. Neuroscience 146:19–30PubMedGoogle Scholar
  105. Yeomans MR, Gray RW (1996) Selective effects of naltrexone on food pleasantness and intake. Physiol Behav 60:439–446PubMedGoogle Scholar
  106. Yeomans MR, Gray RW (2002) Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 26:713–728PubMedGoogle Scholar
  107. Yeomans MR, Wright P (1991) Lower pleasantness of palatable foods in nalmefene-treated human volunteers. Appetite 16:249–259PubMedGoogle Scholar
  108. Zald DH, Hagen MC, Pardo JV (2002) Neural correlates of tasting concentrated quinine and sugar solutions. J Neurophysiol 87:1068–1075PubMedGoogle Scholar
  109. Ziauddeen H, Chamberlain SR, Nathan PJ, Koch A, Maltby K, Bush M, Tao WX, Napolitano A, Skeggs AL, Brooke AC, Cheke L, Clayton NS, Sadaf Farooqi I, O'Rahilly S, Waterworth D, Song K, Hosking L, Richards DB, Fletcher PC, Bullmore ET (2013) Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects. Mol Psychiatry 18:1287–1293PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Elizabeth Murray
    • 1
  • Sietske Brouwer
    • 1
  • Rob McCutcheon
    • 1
  • Catherine J. Harmer
    • 1
  • Philip J. Cowen
    • 1
  • Ciara McCabe
    • 2
  1. 1.Department of Psychiatry, Warneford HospitalUniversity of OxfordOxfordUK
  2. 2.School of Psychology and Clinical Language SciencesUniversity of ReadingReadingUK

Personalised recommendations